PL199614B1 - Ulepszony sposób wytwarzania niehigroskopijnych soli L(-)-karnityny - Google Patents
Ulepszony sposób wytwarzania niehigroskopijnych soli L(-)-karnitynyInfo
- Publication number
- PL199614B1 PL199614B1 PL349894A PL34989400A PL199614B1 PL 199614 B1 PL199614 B1 PL 199614B1 PL 349894 A PL349894 A PL 349894A PL 34989400 A PL34989400 A PL 34989400A PL 199614 B1 PL199614 B1 PL 199614B1
- Authority
- PL
- Poland
- Prior art keywords
- carnitine
- amount
- powder
- mass
- weight
- Prior art date
Links
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical class C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 40
- 150000003839 salts Chemical class 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 13
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 9
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 239000001530 fumaric acid Substances 0.000 claims abstract description 6
- 239000008187 granular material Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 229940095064 tartrate Drugs 0.000 claims description 6
- 239000001358 L(+)-tartaric acid Substances 0.000 claims description 5
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims description 5
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 claims description 2
- 229960001518 levocarnitine Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 abstract description 2
- 239000011975 tartaric acid Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000007711 solidification Methods 0.000 description 7
- 230000008023 solidification Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI000551A IT1312018B1 (it) | 1999-03-19 | 1999-03-19 | Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL349894A1 PL349894A1 (en) | 2002-09-23 |
| PL199614B1 true PL199614B1 (pl) | 2008-10-31 |
Family
ID=11382333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL349894A PL199614B1 (pl) | 1999-03-19 | 2000-03-16 | Ulepszony sposób wytwarzania niehigroskopijnych soli L(-)-karnityny |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6372940B1 (sl) |
| EP (1) | EP1163207B1 (sl) |
| JP (1) | JP2002540094A (sl) |
| KR (1) | KR100664560B1 (sl) |
| CN (1) | CN1147462C (sl) |
| AR (1) | AR023101A1 (sl) |
| AT (1) | ATE247627T1 (sl) |
| AU (1) | AU4105800A (sl) |
| CA (1) | CA2359106A1 (sl) |
| CZ (1) | CZ299312B6 (sl) |
| DE (1) | DE60004649T2 (sl) |
| DK (1) | DK1163207T3 (sl) |
| ES (1) | ES2204555T3 (sl) |
| HK (1) | HK1042468A1 (sl) |
| HU (1) | HUP0200402A3 (sl) |
| IT (1) | IT1312018B1 (sl) |
| NZ (1) | NZ512640A (sl) |
| PL (1) | PL199614B1 (sl) |
| PT (1) | PT1163207E (sl) |
| SI (1) | SI1163207T1 (sl) |
| SK (1) | SK13312001A3 (sl) |
| WO (1) | WO2000056701A1 (sl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2631569B1 (fr) * | 1988-05-20 | 1990-07-27 | Renault Automation | Detecteur de proximite magnetique destine notamment a la decoupe laser |
| ITRM20010030A1 (it) * | 2001-01-23 | 2002-07-23 | Aldo Fassi | Sali di carnitine utili come integratori dietetici/nutrizionali o come farmaci, composizioni che li contengono e procedimenti per la loro pr |
| CN100408579C (zh) * | 2001-02-24 | 2008-08-06 | 贝林格尔英格海姆法玛两合公司 | 黄嘌呤衍生物,其制法及其作为药物组合物的用途 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| CN101209975B (zh) * | 2006-12-29 | 2010-12-01 | 沈阳科硕营养科技有限公司 | 左旋肉碱富马酸钙及其制备方法与用途 |
| WO2009024542A2 (en) * | 2007-08-17 | 2009-02-26 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0917675A2 (pt) * | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | compostos orgânicos para cura de ferida |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| KR20190050871A (ko) | 2010-06-24 | 2019-05-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| EP2425834A1 (en) * | 2010-09-06 | 2012-03-07 | Lonza Ltd. | Process for the production of l-carnitine tartrate |
| JP2012092036A (ja) * | 2010-10-26 | 2012-05-17 | Mitsubishi Rayon Co Ltd | カルニチンの塩の製造方法 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| KR101985384B1 (ko) | 2011-07-15 | 2019-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US20140316156A1 (en) * | 2013-04-18 | 2014-10-23 | Deborah Warner | Method of producing therapeutic agent |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
| CN106748845B (zh) * | 2016-12-23 | 2018-11-20 | 东北制药集团股份有限公司 | 一种左旋肉碱盐微粉的制备方法 |
| KR20190017310A (ko) | 2017-08-10 | 2019-02-20 | 주식회사 셀트리온화학연구소 | 약제학적 성질이 개선된 l-카르니틴 화합물의 염, 이의 제조방법, 이를 함유하는 약학 조성물 |
| JP6964876B2 (ja) * | 2017-11-27 | 2021-11-10 | 株式会社古川リサーチオフィス | オロット酸−カルニチン混合体粉体又はフマル酸−カルニチン混合体粉体の製造方法 |
| CN108383741A (zh) * | 2018-03-16 | 2018-08-10 | 开原亨泰化工有限公司 | 一种制备左旋肉碱成盐的新方法 |
| CN109096129B (zh) * | 2018-09-30 | 2021-04-27 | 东北制药集团股份有限公司 | 一种左旋肉碱酒石酸盐的制备方法 |
| CN109535022B (zh) * | 2018-11-12 | 2022-03-01 | 天津大学 | 一种提高左旋肉碱富马酸盐流动性的制备方法 |
| US20240217920A1 (en) * | 2022-12-28 | 2024-07-04 | Hubei Xujie Pharmaceutical Co., Ltd. | Process for producing l-carnitine |
| US20240228429A1 (en) * | 2023-01-04 | 2024-07-11 | Hubei Xujie Pharmaceutical Co., Ltd | Process for producing l-carnitine |
| CN118638020A (zh) * | 2024-08-08 | 2024-09-13 | 杭州海尔希畜牧科技有限公司 | L-天门冬氨酸l(-)肉碱(1:1)的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3463261D1 (en) * | 1983-12-28 | 1987-05-27 | Sigma Tau Ind Farmaceuti | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
| US5073376A (en) | 1989-12-22 | 1991-12-17 | Lonza Ltd. | Preparations containing l-carnitine |
| IT1289974B1 (it) | 1997-02-25 | 1998-10-19 | Aldo Fassi | Procedimento per la produzione di sali stabili e non igroscopici di l(-)carnitina e di alcanoli l(-)-carnitine |
| CN1177807C (zh) * | 1996-05-31 | 2004-12-01 | 希格马托制药工业公司 | 稳定的、非吸湿性的l(-)肉碱和链烷酰基l(-)肉碱的盐和其制备方法以及含有此盐的固体口服组合物 |
-
1999
- 1999-03-19 IT IT1999MI000551A patent/IT1312018B1/it active
-
2000
- 2000-03-16 CN CNB008034001A patent/CN1147462C/zh not_active Expired - Fee Related
- 2000-03-16 CA CA002359106A patent/CA2359106A1/en not_active Abandoned
- 2000-03-16 PL PL349894A patent/PL199614B1/pl not_active IP Right Cessation
- 2000-03-16 PT PT00920506T patent/PT1163207E/pt unknown
- 2000-03-16 SI SI200030176T patent/SI1163207T1/sl unknown
- 2000-03-16 HU HU0200402A patent/HUP0200402A3/hu unknown
- 2000-03-16 AU AU41058/00A patent/AU4105800A/en not_active Abandoned
- 2000-03-16 US US09/868,980 patent/US6372940B1/en not_active Expired - Fee Related
- 2000-03-16 ES ES00920506T patent/ES2204555T3/es not_active Expired - Lifetime
- 2000-03-16 DE DE60004649T patent/DE60004649T2/de not_active Expired - Lifetime
- 2000-03-16 KR KR1020017010602A patent/KR100664560B1/ko not_active IP Right Cessation
- 2000-03-16 NZ NZ512640A patent/NZ512640A/xx unknown
- 2000-03-16 JP JP2000606564A patent/JP2002540094A/ja not_active Ceased
- 2000-03-16 EP EP00920506A patent/EP1163207B1/en not_active Expired - Lifetime
- 2000-03-16 DK DK00920506T patent/DK1163207T3/da active
- 2000-03-16 WO PCT/EP2000/002344 patent/WO2000056701A1/en active IP Right Grant
- 2000-03-16 SK SK1331-2001A patent/SK13312001A3/sk unknown
- 2000-03-16 CZ CZ20013376A patent/CZ299312B6/cs not_active IP Right Cessation
- 2000-03-16 AT AT00920506T patent/ATE247627T1/de not_active IP Right Cessation
- 2000-03-17 AR ARP000101222A patent/AR023101A1/es unknown
-
2002
- 2002-05-31 HK HK02104080.1A patent/HK1042468A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI990551A1 (it) | 2000-09-19 |
| CA2359106A1 (en) | 2000-09-28 |
| CN1147462C (zh) | 2004-04-28 |
| ES2204555T3 (es) | 2004-05-01 |
| JP2002540094A (ja) | 2002-11-26 |
| IT1312018B1 (it) | 2002-04-04 |
| KR100664560B1 (ko) | 2007-01-03 |
| EP1163207A1 (en) | 2001-12-19 |
| SK13312001A3 (sk) | 2002-05-09 |
| DK1163207T3 (da) | 2003-12-01 |
| CZ20013376A3 (cs) | 2002-02-13 |
| HUP0200402A2 (hu) | 2002-05-29 |
| CN1339023A (zh) | 2002-03-06 |
| ATE247627T1 (de) | 2003-09-15 |
| HK1042468A1 (zh) | 2002-08-16 |
| NZ512640A (en) | 2003-03-28 |
| DE60004649T2 (de) | 2004-03-18 |
| PL349894A1 (en) | 2002-09-23 |
| AU4105800A (en) | 2000-10-09 |
| WO2000056701A1 (en) | 2000-09-28 |
| US6372940B1 (en) | 2002-04-16 |
| KR20010102288A (ko) | 2001-11-15 |
| AR023101A1 (es) | 2002-09-04 |
| HUP0200402A3 (en) | 2002-11-28 |
| CZ299312B6 (cs) | 2008-06-18 |
| EP1163207B1 (en) | 2003-08-20 |
| PT1163207E (pt) | 2003-12-31 |
| SI1163207T1 (sl) | 2003-12-31 |
| DE60004649D1 (de) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL199614B1 (pl) | Ulepszony sposób wytwarzania niehigroskopijnych soli L(-)-karnityny | |
| RU2106140C1 (ru) | Фармацевтическая композиция, способ ее получения, физическая форма n-[4-[5-(циклопентилоксикарбонил)амино-1-метилиндол-3-ил-метил]-3-метоксибензоил]-2-метилбензолсульфонамида, способы ее получения | |
| AU750978B2 (en) | Polymorphic crystalline forms of celecoxib | |
| AU624084B2 (en) | Granular calcium hypochlorite composition and process for preparation thereof | |
| CA1110972A (en) | Tableting of microcapsules | |
| KR20010093759A (ko) | 가루형 만니톨 및 그의 제조방법 | |
| JP5757492B2 (ja) | 製剤用核粒子 | |
| JPH07100653B2 (ja) | 発泡性顆粒及び錠剤の製法及び装置 | |
| KR100587210B1 (ko) | 가티플록사신을 함유하는 다상 구조의 경구 투여용 고형 의약 제제 및 이의 제조방법 | |
| JPH09503522A (ja) | Ｓ（＋）−イブプロフェン粒子の製造方法 | |
| CN117327069B (zh) | 吡咯并喹啉醌二钠盐晶型及其制备方法和应用 | |
| CN104829622A (zh) | 一种枸橼酸西地那非化合物及其药物组合物 | |
| UA80092C2 (en) | Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition | |
| PL176658B1 (pl) | Sposób wytwarzania preparatu farmaceutycznego zawierającego klodronian | |
| SK281041B6 (sk) | Tilidíndihydrogenortofosfát, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje | |
| JPH01102079A (ja) | 球晶状リボフラビンの製造方法 | |
| PL167976B1 (pl) | Sposób wytwarzania 1-hydroksy-2-naftalenokarboksylanowej soli 4-hydroksy-a 1 -[[[6-(4- -fenylobutoksy)- heksylo]amino]metylo]-1,3-benzenodimetanolu w nowej postaci PL PL PL | |
| JPH0674232B2 (ja) | 粒状プロピオン酸ナトリウムの製造方法 | |
| RU2183119C1 (ru) | Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения | |
| FI91633B (fi) | Menetelmä varastoitavan, heksahydraatista ja heptahydraatista koostuvan sinkkisulfaattihydraattiseoksen valmistamiseksi | |
| PL190098B1 (pl) | Mikrocząsteczkowa postać chlorowodorku 1-[2-(2-naftylo)etylo]-4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropirydyny oraz kompozycja zawierająca tę postać | |
| RU2123330C1 (ru) | Способ получения таблетированной формы препарата |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20110316 |